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Background: Colorectal cancer (CRC) is the most frequent cancer in Europe. Randomized clinical trials
demonstrated that screening with fecal occult blood test (FOBT) reduces mortality from CRC. Accordingly, the
European Community currently recommends population-based screening with FOBT. Other screening tests, such as
computed tomography colonography (CTC) and optical colonoscopy (OC), are highly accurate for examining the
entire colon for adenomas and CRC. Acceptability represents a critical determinant of the impact of a screening
program. We designed a randomized controlled trial to compare participation rate and diagnostic yield of FOBT,
CTC with computer-aided diagnosis, and OC as primary tests for population-based screening.
Methods/Design: A total of 14,000 subjects aged 55 to 64 years, living in the Florence district and never screened
for CRC, will be randomized in three arms: group 1 (5,000 persons) invited to undergo CTC (divided into: subgroup
1A with reduced cathartic preparation and subgroup 1B with standard bowel preparation); group 2 (8,000 persons)
invited to undergo a biannual FOBT for three rounds; and group 3 (1,000 persons) invited to undergo OC. Subjects
of each group will be invited by mail to undergo the selected test. All subjects with a positive FOBT or CTC test
(that is, mass or at least one polyp ≥6 mm) will be invited to undergo a second-level OC. Primary objectives of the
study are to compare the participation rate to FOBT, CTC and OC; to compare the detection rate for cancer or
advanced adenomas of CTC versus three rounds of biannual FOBT; to evaluate referral rate for OC induced by
primary CTC versus three rounds of FOBT; and to estimate costs of the three screening strategies. A secondary
objective of the study is to create a biological bank of blood and stool specimens from subjects undergoing CTC
and OC.
Discussion: This study will provide information about participation/acceptability, diagnostic yield and costs of
screening with CTC in comparison with the recommended test (FOBT) and OC.
Trial registration: ClinicalTrials.gov Identifier: NCT01651624.
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Colorectal cancer (CRC) is the most frequent cancer in
Europe. In 2008, 436,000 persons were diagnosed with
CRC and 212,000 persons died from the disease [1]. In
Italy, between 2003 and 2005, CRC was the fourth most
frequent neoplastic disease in males and the third in fe-
males. It was also the second leading cause of cancer
death both in males and females. In Italy 20,457 new
cases of CRC in males and 17,276 in females are esti-
mated to occur every year [2].
A combination of early detection and improvement
of treatment increases survival rate for CRC [3]. In
particular, the removal of its precursor lesion (aden-
oma) decreases both the incidence and mortality of
CRC [4], and population screening of asymptomatic
average risk persons reduces the incidence and mor-
tality rate for CRC [5-10].
Currently, several potential screening tests including
fecal occult blood test (FOBT), flexible sigmoidoscopy
(FS), optical colonoscopy (OC) and computed tomog-
raphy colonography (CTC) are available and variably
recommended by scientific societies [11,12]. FOBT is a
simple, cheap and safe laboratory test that relies on the
assumption that asymptomatic CRC and large adenomas
may bleed. For this reason it is affected by false negative
results due to, for example, incorrect storage of sample
or drug assumption, and is affected by false positive re-
sults due to hemorrhoids or diet and medications in case
of guaiac test [11]. All the other examinations, varying in
complexity and costs, allow direct depiction of CRC or
adenomas but suffer procedural risks (that is, complica-
tions, such as colonic perforation) or biological risks
(that is, ionizing radiation exposure) [11].
So far, three randomized clinical trials (RCT) demon-
strated that screening with FOBT reduces mortality from
CRC in comparison to a no-screening condition [5-7].
Moreover fecal immunochemical test (FIT) showed a bet-
ter sensitivity-specificity ratio and cost-effectiveness than
guaiac test for search of fecal occult blood [13-15].
Screening programs with immunochemical FOBT have
been implemented in several regions of Italy [16] and in
the Tuscany region such a program has been active since
2000 under the coordination of the Cancer Research and
Prevention Institute (ISPO) [17]. ISPO is an institution
of the Tuscany Health Service, which aims to organize,
realize and monitor clinical and research activities in
population-based screening programs for breast, cervical
and colorectal cancer in the Tuscany region of Italy [18].
CRC screening is offered to all subjects aged 50 to 70
years who are invited by mail every second year to
undergo immunochemical FOBT. Subjects with a nega-
tive FOBT are notified of their test results by mail and
advised to repeat screening after two years. Subjects with
a positive test are invited to undergo total OC [17].Unlike FS, both OC and CTC enable exploration of the
entire colon length. OC is widely accepted as the gold
standard procedure for detection of colorectal neoplasia,
but there is no evidence that OC screening is effective in
reducing mortality for CRC, although indirect data show
that this strategy may contribute to a 76 to 90% decrease
of the incidence for CRC [4]. Moreover, screening with
OC in selected cohorts of subjects by detection and re-
moval of most advanced adenomas could allow long
screening intervals [19,20]. The major disadvantages of
OC as a screening test are its complications, including
bleeding and perforation, and the discomfort due to both
full bowel preparation and the procedure itself [21]. As a
matter of fact, attendance at an OC as primary screening
test for CRC is quite low [22].
CTC is a minimally invasive examination. A recent
meta-analysis showed that CTC has 96.1% sensitivity for
CRC [23]. In two large trials conducted on asymptom-
atic individuals at average risk for CRC, CTC showed
high per-patient accuracy for adenomas larger than 10
mm with 92.2% to 96% sensitivity and 86% to 96% speci-
ficity [24,25]. In another large study the diagnostic yield
for advanced neoplasia of CTC (3.2%) was similar to that
of OC (3.4%) [26]. Notably, the risk of complications
from CTC is extremely low, particularly in asymptom-
atic subjects [27-29].
The need of bowel preparation for CTC can adversely
influence acceptability of this screening test. However lim-
ited bowel preparations reducing the subject’s discomfort
are now available [30]. A distinctive disadvantage of CTC
is exposure of the subject to ionizing radiation, but use of
low-dose protocols limits this concern [31].
A distinguishing feature of CTC as compared to FS
and OC is that it enables visualization of abdominal or-
gans external to the colon. The prevalence of significant
extracolonic findings can be quite high and was about
6% in a large screening cohort [32]. Admittedly, detec-
tion of extracolonic findings can be beneficial but can
also generate anxiety in the subject and induce further
costly diagnostic examinations.
A final operational aspect that has to be considered
when CTC is used as primary screening test for CRC is
that CTC reading may be time consuming and fatiguing
for the radiologist. Computer-aided diagnosis (CAD) sys-
tems have been developed in order to help the radiologist’s
detection of colorectal polypoid lesions. The use of CAD
as a second reader improves sensitivity of CTC [33]. The
use of CAD as a first reader could be particularly useful in
a screening setting, and available data suggest that CAD
as first reader is associated with similar per-polyp and per-
patient sensitivity as compared to unassisted reading [34].
The optimal screening test for CRC has not been
established yet. FS and FOBT reduce incidence and/or
mortality for CRC. However, they do not explore the
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completely satisfactory.
To date, two RCTs investigated participation rate in
CTC population screening [35,36]. In the Australian trial,
participation rate was 28.4% [35]. In the Dutch study
8,844 subjects aged 50 to 75 years were randomly allo-
cated (2:1) to be invited for primary screening for CRC by
OC or CTC. Participation rate in the CTC group was sig-
nificantly higher than participation in the OC group (34%
versus 22%), whereas diagnostic yield for advanced neo-
plasia was similar for the two screening tests [36].
We designed and report herein the protocol of a RCT
comparing participation rate, diagnostic yield and costs
of a population-based screening program for colorectal
cancer with FOBT, CTC and OC in the Florence district
of Italy (SAVE study).Methods/Design
Objectives
The primary objectives of this study are:
1. To compare the participation rate to FOBT, CTC
and OC as primary screening tests in a population-
based program for CRC.
2. To compare the participation rate to CTC with
reduced cathartic preparation versus CTC with
standard bowel preparation.
3. To compare the detection rate for cancer or
advanced adenomas of CTC with CAD versus three
rounds of FOBT every second year.
4. To evaluate the referral rate for OC induced by
primary CTC versus three rounds of FOBT every
second year.
5. To compare the costs of the three screening
strategies using an activity-based costing model.
The secondary objectives of this study are:
1. To compare the expected and perceived discomfort
of CTC and OC as assessed with a structured
questionnaire.
2. To evaluate the rate of complications in each
screened group.
3. To create a biological bank of blood and stool
specimens from subjects who undergo CTC,
screening OC and second-level OC.Study design and population
The study will be a prospective RCT with three arms
(Figure 1). The target of our study will be a cohort of
14,000 subjects aged 55 to 64 years who live in the
Florence district of Italy and have never been screened
before, who will be drawn from the population files ofthe Florence Municipality, and who will be randomized
into three groups of different sizes as follows:
1. Group 1 will consist of 5,000 persons invited to
undergo CTC. This group will be divided into two
subgroups; subgroup 1A will be invited to undergo
CTC with reduced cathartic preparation (see below)
and subgroup 1B that will be invited to undergo
CTC with standard bowel preparation (see below).
2. Group 2 will consist of 8,000 persons invited to
undergo FOBT every second year for three rounds,
according to the current procedure of the regional
screening protocol.
3. Group 3 will consist of 1,000 persons invited to
undergo OC.
Simple randomization will be performed by personnel
of the epidemiology unit of ISPO in a single procedure
using STATA software version 12 (www.stata.com).
Randomization of married people will be forced; that is,
individuals will be assigned to the same arm of their
husband/wife, to prevent subjects’ requests to be allo-
cated to another group. Invitees and investigators will
not be masked from the allocation.
Invitation procedure
A specialized database will be created at ISPO and
will be used for the invitation procedure, which will
start in September 2012 and will end in December
2013. All target subjects will be invited to the se-
lected screening test by mail.
Individuals of each group will receive an invitation letter
and an information leaflet. Four different information leaf-
lets will be used, one for each group/subgroup. The leaf-
lets contain information about CRC, importance of
screening, and advantages and possible risks of the se-
lected test. The leaflets are based on those used in the re-
gional screening program and underwent an internal
validation procedure using the ‘focus group technique’,
which involved ten ISPO employees aged 55 to 64 years.
The invitation letter for the FOBT group also contains in-
structions on how to collect the test kit at the nearest
pharmacy. The invitation letter for the CTC and the OC
also contains a phone number and an email address for
the screening center. All invitees have the option to call or
to send an email to the screening center in order to make
an appointment for a consultation. All non-responders
will receive a reminder by mail after three months. Non-
responders to the reminder will be invited to undergo
FOBT according to current screening procedure.
Consultation
Subjects who accept an invitation for CTC or OC will
have a preliminary consultation at the screening center
14,000 SUBJECTS LIVING  IN 
THE DISTRICT OF FLORENCE
RANDOMIZED
5,000 SUBJECTS
INVITED BY MAIL TO CTC
8,000 SUBJECTS INVITED BY 
MAIL TO FOBT FOR 3 BIANNUAL 
ROUNDS
1,000 SUBJECTS INVITED BY 
MAIL TO TOTAL COLONOSCOPY
2,500 
SUBJECTS 
INVITED BY 
STANDARD 
PREP
2,500 
SUBJECTS 
INVITED BY 
MAIL TO  
CTC WITH 
MAIL TO  
CTC WITH 
REDUCED 
PREP
PHONE CONSULTATION 
FACE TO FACE CONSULTATION
CT COLONOGRAPHY
IF POSITIVE: REFERRAL TO 
TOTAL COLONOSCOPY
KIT DELIVERY AT PHARMACIES
NEGATIVE
FOBT
POSITIVE
FOBT
INVITATION 
FOR THE 
NEXT FOBT 
ROUND
REFERRAL TO 
TOTAL 
COLONSCOPY
PHONE CONSULTATION
FACE TO FACE CONSULTATION
COLONOSCOPY
Figure 1 Study design. Flow chart.
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be informed about the study protocol, the screening
examination, the bowel preparation, and management in
case of positive results. Moreover, information concerning
biological banking will be given. Informed consent for par-
ticipation to the study and for biological banking will be
requested at the end of the consultation. Subjects will then
be scheduled for the selected examination (CTC or OC).Exclusion criteria
Before randomization, the selected cohort of subjects
will be matched with the archive of ISPO in order to ex-
clude from the study subjects with a personal history of
CRC or with advanced adenomas, inflammatory bowel
disease, complete OC in the last five years, or FOBT in
the last two years. Also, subjects who report one of the
above-mentioned conditions at the preliminary consult-
ation would be excluded from the study.Primary screening tests
Fecal occult blood test
The FOBT screening test adopted is OC-SENSOR DIANA
(Eiken Chemical Co., Tokyo, Japan), a quantitative, com-
pletely automated immunochemical test, based on latex
agglutination. Positivity threshold is set at 100 ng hemo-
globin/ml of sample solution. According to the current
screening procedure, subjects are invited to collect the test
kit in any of the pharmacies of the district of Florence and
to return fecal specimens to one of the seven collection
points in town. Specimens are processed at the ISPO la-
boratory, usually within one week.
Computed tomography colonography
Subjects of subgroup 1A will receive a reduced cathartic
preparation consisting of a three-day, low fiber diet and
the administration of 13.8 g of macrogol 3,350
(MOVICOL, Norgine, Milano, Italy) diluted in a glass of
water at the three main meals for three days before the
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standard bowel preparation consisting of a five-day, low
fiber diet and a two-liter solution of polyethylene glycol
(MOVIPREP, Norgine, Milano, Italy) followed by two li-
ters of clear liquid the day before the examination.
In both subgroups fecal tagging will be obtained with 70
ml of iodinated oral contrast agent (GASTROGRAFIN,
Bayer Schering Pharma AG, Berlin, Germany) adminis-
tered three hours before the procedure. Colonic distension
will be performed by a radiologist using an automatic
carbon-dioxide insufflator (PROTOCO2L, Bracco, EZEM,
Lake Success, USA), after intravenous administration
of 20 mg of scopolamine butylbromide (BUSCOPAN,
Boehringer Ingelheim Italia, Milan, Italy), if not contrain-
dicated (for example, hypersensitivity to scopolamine
butylbromide or to any of the product inactive ingredients;
untreated narrow angle glaucoma; or prostatic hyper-
trophy with urinary retention).
CTC will be performed in two different hospitals in
the Florence district (Azienda Ospedaliero Universitaria
Careggi, Nuovo Ospedale S. Giovanni di Dio). Then CTC
data will be transferred to a centralized reading center for
interpretation, through the RIS/PACS metropolitan area
network using uncompressed Digital Imaging and Com-
munications in Medicine (DICOM) standard format.
CTC will be performed with 16 or 64 rows of detectors
CT scanner using a low-dose protocol (16 rows of detec-
tors: collimation 16 × 0.75 mm, section width 1 mm, pitch
1.25, rotation time 0.5 s, 120 kVp, 50 effective mAs; 64
rows of detectors: collimation 32 × 0.6 mm, section width
1 mm, pitch 1.4, rotation time 0.5 s, 120 kVp, 50 effective
mAs). The radiologist and technician performing the CTC
acquisition will receive special training for the colonic dis-
tension and scanning procedure.
In the reading center each CTC will be evaluated by a
radiologist using CAD as the first reader (CADCOLON,
Im3D, Turin, Italy). First, the radiologist will examine
the polyp candidates proposed by CAD using 2D images
with 3D view for problem solving. Then he/she will per-
form a quick unassisted 2D reading, again supplemented
by 3D for problem solving, to look for lesions missed by
CAD. Each radiologist involved in the CTC evaluation is
required both to have read at least 300 examinations
and to have completed a qualified test based on a series
of 30 endoscopically verified CTCs achieving per-patient
sensitivity and specificity of at least 90% for lesions ≥6
mm. Two to five CTC readers will be recruited for the
study.
CTC-detected lesions will be recorded according to
their morphology (sessile, pedunculated, flat, vegetating,
stenosing), location (rectum, sigmoid, descending, trans-
verse, ascending and cecum) and maximum diameter on
2D images. Flat lesions will be defined as a polyp with
height less than 3 mm above the mucosal surface [37].Polyps smaller than 6 mm will be annotated but will not
be mentioned in the final report. CTCs will be reported
according to the CT Colonography Reporting and Data
System (C-RADS) classification [37]. No special effort
will be performed to look for extracolonic findings. Rele-
vant extracolonic findings (C-RADS E3, E4) seen by the
radiologist during quick axial images scrolling will be
annotated and communicated to the subject in the
screening center [37]. Less important extracolonic find-
ings (for example, gallstones) will not be reported. Diag-
nostic examinations generated by relevant extracolonic
findings will not be recorded. CTC reading times will be
annotated.
Optical colonoscopy
All primary screening colonoscopies will be performed at
the endoscopy unit of the ISPO by the same endoscopist
with particular experience in screening. All participants
will be prepared by low fiber diet for five days and by oral
intake of two liter of a polyethylene glycol solution
(MOVIPREP, Norgine, Milan, Italy) followed by two liter of
clear liquid the day before the examination. OC will be
performed under deep sedation with Propofol (DIPRIVAN,
AstraZeneca, Milan, Italy), unless deep sedation is refused
by the subject. Sedation will be administered by an
anesthesiologist who will always be present in the endos-
copy room during examinations. All detected lesions
will be measured with open biopsy forceps and annotated
according to size, macroscopic aspect (sessile, pedun-
culated, flat, vegetating, stenosing, or ulcerated), and
localization (rectum, sigmoid, descending, transverse, as-
cending and cecum). Definition of flat lesions will be the
same as used for CTC.
Pathology
All colorectal lesions will be defined according to the
WHO criteria [38] as follows: hyperplastic, serrated,
tubular, tubular-villous or carcinoma lesion. Advanced
adenoma is defined as any adenoma greater than 9 mm
and/or with a villous histological component greater
than 20%, and/or with severe dysplasia. One or two ex-
perienced gastrointestinal pathologists will evaluate
histopathology.
Complications
Complications of CTC and OC that occur within 30 days
after the procedures will be recorded. All complications
will be detailed according to type, timing, severity, treat-
ment and outcome. Complications that arise during CTC
and OC, or immediately afterward, will be annotated in
the study database. Information about subsequent compli-
cations will be collected through self-reporting, telephonic
questionnaire administered one month after the examin-
ation and hospital discharge database.
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Fecal occult blood test All subjects with a negative
FOBT will receive a mail notification of the result with
the indication to repeat the FOBT after two years. All
subjects with a positive FOBT will be invited to
undergo OC.
Computed tomography colonography Participants
with no lesions or with polyps <6 mm at CTC will be
classified as negative. They will be informed of the result
by mail within three weeks. This cohort of subjects will
be scheduled for invitation to undergo a FOBT after five
years. In the case of CTC revealing at least one polyp of
6 mm (C-RADS 2), or larger lesions (C-RADS 3 to 4),
subjects will be contacted by phone within two weeks
and invited to undergo OC. Subjects with relevant
extracolonic findings will be contacted by phone and in-
vited to the screening center for a consultation with the
radiologist.
Optical colonoscopy Participants undergoing OC will
be informed about the result immediately after the pro-
cedure. In case of polyps or cancer, histopathology as-
sessment will provide the definitive diagnosis, and
participants will be informed about the results in three
weeks. In case of cancer, subjects will be referred for
treatment and follow-up.
Second level colonoscopy
OC in subjects with a positive FOBT or CTC will be
performed at the endoscopy unit of the ISPO by the
same operator and according to the procedure detailed
above. All individuals will be informed about the result
of the examination using the same procedure as primary
screening OC. Subjects with a positive CTC or FOBT
who refuse OC assessment will receive a reminder letter
containing information about the need for further diag-
nostic examination. In these cases the option of follow-
up CTC will not be offered.
Biological banking
A secondary objective of the study is creation of a bio-
logical bank, which will be undertaken as indicated
below:
1. In the CTC group, blood samples will be collected
in all subjects who consent to it. Moreover, stool
specimens will be collected from subjects with a
positive CTC referred to OC.
2. In the FOBT group, all positive subjects referred to
OC will be asked to undergo blood and stool
sampling at the time of the latter.
3. In the OC group, all attendees will be requested to
undergo blood and stool sampling.Pathological specimens of subjects surgically treated will
be collected. Informed consent for sampling and banking
will be obtained, according to the European Community
directives [39]. All samples will be immediately transferred
and stored at −80°C in dedicated freezers at the ISPO. A
database will be created in order to manage the stored
samples and related clinical information.
Questionnaires
Acceptability of the test represents a critical determinant
of the expected screening benefit [40]. Therefore, we will
investigate several issues related to the proposed screening
test through structured questionnaires administered at
three time points to all participants of the CTC group and
of the OC group. First, a questionnaire evaluating discom-
fort due to bowel preparation and subject’s expectations
for the selected examination will be administered immedi-
ately before CTC and primary screening OC. A second
questionnaire investigating procedural discomfort will be
administered immediately after CTC and OC. A third
questionnaire investigating all aspects of the screening
procedure will be administered by telephonic interview
one month after the examination.
Ethical approval
The study protocol was approved by the Ethical Commit-
tee of the Local Health Unit of Florence (Azienda Sani-
taria Firenze), number 432/2010/OSS/C.E.L.
Data analyses
Statistical analyses will be performed using the STATA
software version 12.0 and will be based both on the
intention-to-treat and the per-protocol principle. Notably,
in the intention-to-treat analysis, subjects with a positive
CTC who refuse to undergo colonoscopy will be classified
as CTC pathway ‘negative’ for advanced adenomas.
We will calculate the participation rate for each screen-
ing procedure as the number of participants undergoing
the screening test relative to the total number of invitees.
Using the chi-square test we will assess if the CTC group
will achieve a statistically significant difference in partici-
pation as compared to the OC group. Additionally, we will
test to determine if better participation will be achieved
with reduced as compared to standard cathartic bowel
preparation for CTC.
The detection rate of the screening test is defined as
the proportion of subjects with screen detected cancer
and/or advanced adenoma over the total number of sub-
jects screened. The most advanced detected lesion per
screened subject will be used to calculate the detection
rate. We will test to see if a statistically significant differ-
ence exists between the detection rate of a single round
of CTC and the cumulative detection rate of three
rounds of FOBT.
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as the proportion of subjects attending screening CTC
who, being positive to CTC, will be invited to undergo OC.
Sample size
Comparison of CTC versus OC with endpoint ‘compliance to
the invitation’
A total of 1,000 people were invited to participate in the
OC group, with the assumption that 30% of those in-
vited would adhere to the invitation. This assumption is
based on data from the SCORE3 trial, where adherence
to colonoscopy in the Florence district was 27.9% [22].
In the CTC group we invited 5,000 subjects with an
expected participation of 35%. Thus it will be possible to
detect as statistically significant a difference of more
than 3.1% with a two-tailed test and of more than 2.6%
with a one-tailed test, setting the value of the alpha error
equal to 5% (power = 0.80).
Comparison of CTC with reduced preparation versus CTC
with standard preparation
A total of 2,500 subjects were invited to participate in
the CTC subgroup with reduced preparation, and 2,500
subjects were invited to participate in the CTC subgroup
with standard preparation. In this way, it will be possible
to detect, as statistically significant, a difference of more
than 2.6% with two-tailed test and of more than 2.2%
with a one-tailed test, by setting the value of the alpha
error equal to 5% (power = 0.80).
Estimation of the recall rate to OC in the CTC arm
With a sample size of 5,000 subjects we will be able
to estimate the recall rate to OC (assuming a true posi-
tivity rate equal to 15%) with an uncertainty of +/−2.5%.
(alpha = 0.05; power = 0.80).
Comparison of detection rate for colonic lesions between a
single round of CTC and three rounds of FOBT
A detection rate for advanced adenomas or carcinomas
equal to 5% is expected for CTC. In the group of 8,000
subjects invited to undergo FOBT, an adherence to invita-
tion of about 50% was assumed. If the cumulative detec-
tion rate for advanced adenomas and carcinomas of three
FOBT rounds will be less than 4%, a statistically significant
difference (alpha = 0.05, power = 0.80, one tail) with the
detection rate of a single round of CTC will be revealed.
Discussion
FOBT and FS are currently recommended for population-
based screening programs in Italy, and are employed in
several regions [16]. Moreover, the European Guidelines
on quality assurance for CRC screening has recently
recommended FIT as the first choice test in place of the
guaiac test [41].CTC has been demonstrated to be an accurate tech-
nique that permits a minimally invasive structural evalu-
ation of the whole colon [23-29]. In our study we will
basically compare diagnostic yield of CTC versus three
rounds of biannual FIT. In fact, efficacy of FOBT in redu-
cing mortality from CRC relies on the cumulative sensitiv-
ity that the test offers round by round. Thus, a correct
assessment of diagnostic yield of the two screening strat-
egies has to be carried out comparing a single CTC exam-
ination with a number of FOBT rounds approximate to
the suggested rescreening interval of CTC, namely five
years [11,12].
So far, data about adherence to CTC invitation in com-
parison with FIT are not available in the setting of a
population-based screening program. Many other aspects
concerning a potential role of CTC as first level screening
test have not been evaluated yet. These include the impact
of referral rate to OC in CTC positive subjects and the es-
timate of OC workload and costs of CTC screening as
compared to both OC and FOBT-based screening.
Acceptability represents a critical determinant of the im-
pact of a screening program. High participation of invited
people can be obtained if the offered screening test is well
accepted. The acceptability of CTC can be enhanced if the
examination is performed without an extensive bowel
preparation as the one required for OC [42,43]. Up-
to-date large trials evaluating accuracy of CTC in asymp-
tomatic average risk subjects were conducted either using
full laxative preparation with fecal tagging or employing
reduced bowel preparation [24,25,44]. Also the Dutch
study used a limited bowel preparation [36]. Thus, it is of
interest to evaluate how different bowel preparations
influence attendance to CTC screening.
In our study we utilize a teleradiological model of CTC
reading, which consists of performing the examination in
the hospitals near the citizen’s house and sending datasets
via the RIS/PACS metropolitan area network to a central-
ized reporting unit. Reading centralization is expected to
improve the quality of a radiologist’s reading performance.
It will be also of interest to evaluate how the avail-
ability of the test near the subject’s house could en-
hance attendance.
In our study CTC will be interpreted using a CAD sys-
tem as the first reader. This reading modality could re-
duce reading time and have a positive impact on costs of
screening with CTC.
We will also compare CTC and FIT screening with
OC as a first-level test. OC is widely accepted as the
diagnostic gold standard for the detection of CRC and as
such represents the mandatory second-level examination
after positive FOBT or CTC screening tests. However
OC has a low acceptance among individuals at average
risk of the disease, and this critical aspect hinders its use
as a primary screening test [22].
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test in a population-based program of CRC prevention
will provide information about participation/acceptabil-
ity, diagnostic yield and costs of this test in comparison
with the recommended test (FOBT) and with OC.
Trial status
The trial started recruitment in January 2013.
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